Expanded Access for Dasatinib

Bristol-Myers Squibb (BMS)

Status

Conditions: Leukemia

Treatments: Drug: Dasatinib

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT00454753

CA180-109

Details and patient eligibility

About

This is an expanded access designed to provide access to dasatinib for eligible participants.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria